On March 30, 2026, BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the submission of its New Drug Application (NDA) to the FDA for BBP-418, an oral treatment aimed at individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This submission is significant as it includes interim Phase 3 FORTIFY data that demonstrates BBP-418's rapid and consistent treatment effect, along with a favorable safety profile. The data indicates statistically significant and clinically meaningful improvements in both ambulation and pulmonary function for patients. BridgeBio's CEO, Christine Siu, emphasized the importance of this NDA submission, stating it brings the company closer to delivering the first approved therapy for a condition that has long awaited meaningful treatment options. The company anticipates FDA approval and a U.S. launch in late 2026 or early 2027. If approved, BBP-418 could become the first and only therapy for LGMD2I/R9, marking a historic milestone in the treatment of limb-girdle muscular dystrophy. The company is also exploring expedited approval pathways in Europe, further highlighting its commitment to addressing the unmet needs of patients with this rare condition. The NDA submission has been bolstered by positive results from the Phase 3 clinical trial, which met all primary and secondary endpoints in its interim analysis. This development is expected to have a large positive effect on BridgeBio's stock price, reflecting the potential market impact of BBP-418 as a groundbreaking treatment option.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.